{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008133","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.599119+00:00","generated_at":"2026-06-02T00:41:20.262313+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"KALA BIO Q1 net loss $11.8M; Phase 2b CHASE trial enrolling, topline data by year-end 2024","bullets":["Phase 2b CHASE trial of KPI-012 for PCED enrolling; topline data expected by year-end 2024.","Cash and equivalents $48.5M as of March 31, 2024; with CIRM award, funds operations into Q3 2025.","Q1 2024 net loss $11.8M ($4.20/share) vs $14.5M ($6.99/share) in Q1 2023; operating loss $11.9M.","R&D expenses rose to $6.4M from $4.0M year-over-year, driven by KPI-012 development.","Gross proceeds of $8.6M from March 2024 private placement partially offset cash used in ops."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008133","json":"https://secwatch.observer/filing/0001558370-24-008133.json","markdown":"https://secwatch.observer/filing/0001558370-24-008133.md","text":"https://secwatch.observer/filing/0001558370-24-008133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024008133/0001558370-24-008133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024008133/kala-20240514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:41:20.262313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fac66f9f23a08c1cf37b9b9b6c3d5445ed4671b4","claim":"KALA BIO, Inc. reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 14, 2024, KALA BIO, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a general business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837024008133/0001558370-24-008133-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}